BridgeBio Oncology Therapeutics (BBOT) EBITDA (2024 - 2026)

BridgeBio Oncology Therapeutics has reported EBITDA for 3 years, with the latest figure at -$46.2 million in Q1 2026.

• Quarterly EBITDA fell 99.59% year-over-year to -$46.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$139.9 million (down 115.77% YoY) and the FY2025 annual result came in at -$145.8 million, down 80.33% from the prior year.
• EBITDA slipped to -$46.2 million in Q1 2026 per BBOT's latest filing, from -$43.4 million in the prior quarter.
• Over five years, EBITDA peaked at -$66701.0 in Q1 2024 and troughed at -$49.2 million in Q3 2025.
• A 3-year average of -$22.8 million and a median of -$21.9 million in 2024 frame the typical range for EBITDA.
• The widest YoY moves for EBITDA: up 98.4% in 2025, down 34587.64% in 2025.
• Over 3 years, EBITDA stood at -$21.9 million in 2024, then plunged by 98.4% to -$43.4 million in 2025, then dropped by 6.38% to -$46.2 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered -$46.2 million, -$43.4 million, and -$49.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.